AL002
Early Alzheimer's Disease
Phase 2Active - INVOKE-2 trial enrollment completed
Key Facts
Indication
Early Alzheimer's Disease
Phase
Phase 2
Status
Active - INVOKE-2 trial enrollment completed
Company
About Alector
Alector is a clinical-stage biotech company with a mission to conquer neurodegenerative diseases by modulating the immune system. Its strategy is validated by major partnerships with GSK and AbbVie, and it is advancing a late-stage pipeline led by latozinemab in Phase 3 for frontotemporal dementia. The company's proprietary Alector Brain Carrier (ABC) platform aims to solve the critical challenge of blood-brain barrier delivery, positioning it at the forefront of a novel therapeutic paradigm.
View full company profileTherapeutic Areas
Other Early Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| AD04™ | ADvantage Therapeutics | Phase 2 |
| IBC-Ab002 | ImmunoBrain Checkpoint | Phase 1 |
| Lecanemab (Leqembi®) | bioarctic-ab | Approved |
| AL101 / GSK4527226 | Alector | Phase 2 |
| Sabirnetug (ACU193) - Intravenous (IV) | Acumen Pharmaceuticals | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Acumen Pharmaceuticals | Phase 1 |